Genetic counseling

Global and Regional Rare Disease Genetic Testing Market Report 2023-2033: Early Detection Demand and Innovative Systems Usher in New Era for Rare Disease Genetic Testing

Retrieved on: 
Tuesday, October 3, 2023
Chromosome, DNA, Sanger, National Centre for Foreign Animal Disease, Gastroenterology, Prevalence, BGI Group, DSM-IV codes, Serum, Disease, Fetus, Genomics, Parent, Hospital, Cardiogenic shock, SRL Diagnostics, NGS, Amniocentesis, CVS, Genetic testing, Research, Birth, Genetic code, Exome, Incidence, Genetic counseling, Plasma, Metabolism, Patient, Polymerase chain reaction, Physician, Risk, State Key Laboratories, WGS, Inherit, Growth, Diagnosis, Region, R, Rare, WES, SNV calling from NGS data, Massive parallel sequencing, Gene, PCR, Genome, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.

Key Points: 
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • Among the most prevalent rare disease genetic testing panels are those tailored for gastroenterology, endocrine and metabolic disorders, and neurological diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Montefiore Einstein Comprehensive Cancer Center Unveils New Destination for Breast Care

Retrieved on: 
Thursday, September 28, 2023
Albert Einstein College of Medicine, BOLD, GE HealthCare, Lymphedema, Surgical oncology, Radiation, Surgeon, Hair loss, 3D, Clinical trial, GE, Woman, Research, Element, Anesthesia, Genetic counseling, Incidence, Montefiore, Breast, Patient, Physician, Head, Diagnosis, Health, Mammography, Breast cancer, Medical imaging, Birth control, Pharmaceutical industry, Radiology

BRONX, N.Y., Sept. 28, 2023 /PRNewswire/ -- Yesterday, Montefiore Einstein Comprehensive Cancer Center (MECCC) opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place. The center is home to some of the nation's top breast cancer physicians, surgeons and researchers. It offers screening studies, advanced imaging, minimally invasive surgery, plastic & reconstructive surgery, a high-risk breast cancer prevention and lymphedema prevention program, as well as genetic counseling under one roof. Services like medical & radiation oncology, nutrition, and access to MECCC's Bronx Oncology Living Daily (BOLD) wellness and support program, are also available. The goal of the breast center is to provide every patient with an unparalleled level of evaluation and care.

Key Points: 
  • Comprehensive Breast Services & the Most Advanced Technology Available in a New, Healing Environment
    BRONX, N.Y., Sept. 28, 2023 /PRNewswire/ -- Yesterday, Montefiore Einstein Comprehensive Cancer Center (MECCC) opened a new state-of-the-art breast center at the Hutchinson Metro Center at 1250 Waters Place.
  • The center is home to some of the nation's top breast cancer physicians, surgeons and researchers.
  • The goal of the breast center is to provide every patient with an unparalleled level of evaluation and care.
  • For more information about the breast center and MECCC's research and patient care, including its High-Risk Prevention and Surveillance program, visit cancer.montefioreeinstein.org.

Dr. Gary Nakhuda to Present Insights on Mosaic Embryo Transfer at CFAS Annual Meeting 2023

Retrieved on: 
Thursday, September 21, 2023
Olive, Transfer, Reproductive medicine, Pregnancy, PGT, Patient, NGS, DNA sequencing, Mosaic, Research, Multimedia, Cell, IVF, Science, Genetic counseling, Fertility, Genetic testing, Knowledge, Literature, Mosaic (genetics), Conference, NIPT, Birmingham Women's Fertility Centre, Medical device, Silviculture, Birth control, Aneuploidy

VANCOUVER, British Columbia, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce the participation of its co-founder and co-director, Dr. Gary Nakhuda, as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023, an annual meeting of professionals in reproductive medicine and science.

Key Points: 
  • VANCOUVER, British Columbia, Sept. 21, 2023 /PRNewswire-PRWeb/ -- Olive Fertility Centre is pleased to announce the participation of its co-founder and co-director, Dr. Gary Nakhuda, as a featured speaker at the Canadian Fertility and Andrology Society (CFAS) Conference 2023, an annual meeting of professionals in reproductive medicine and science.
  • Furthermore, Dr. Nakhuda will discuss insights from Olive's extensive data and experience with PGT-A, adding an invaluable layer of real-world context to the discussion.
  • Dr. Gary Nakhuda explains, "Embryonic mosaicism refers to the co-existence of cells with normal chromosome complements and others with apparent abnormalities.
  • Dr. Gary Nakhuda's presentation promises to be a significant contribution to the CFAS 2023 event, offering valuable insights that could shape the future of reproductive medicine.

EveryLife Foundation Study Measures Economic Impact of Delayed Diagnosis of Rare Diseases

Retrieved on: 
Thursday, September 14, 2023
Research, Congressional News, Views, Public Policy, Government, Healthcare Reform, Health, State, Local, General Health, Other Science, Science, Bureau of Labor Statistics, Workforce, Medicine, Medicaid, Life, New Era, ALD, Bureau, Survival, Quality of life, Pfizer, Glycogen storage disease type II, Pharmacy, Anatomical pathology, Diagnosis, Patient engagement in Canada, Occupational therapy, Genetic counseling, FXS, Genetic testing, UnitedHealth Group, Pharmaceutical Research and Manufacturers of America, Sibling, DMD, Alexion Pharmaceuticals, HIV disease progression rates, American College of Medical Genetics and Genomics, Patient, Pediatrics, Physician, Clutch (eggs), Sanofi, Rare, Amicus Therapeutics, Mortality, Infant, American College, Medical genetics, Disease, Medical imaging, Medical device, Pharmaceutical industry, SCID, Genomics, Genentech, Ultragenyx, Optum, Policy

This new study on the Cost of Delayed Diagnosis is a follow-up to the landmark 2021 “ National Economic Burden of Rare Disease Study ,” which estimated that the economic impact of 379 rare diseases in 2019 was nearly $1 trillion, with 60% of those costs being shouldered directly by families and society.

Key Points: 
  • This new study on the Cost of Delayed Diagnosis is a follow-up to the landmark 2021 “ National Economic Burden of Rare Disease Study ,” which estimated that the economic impact of 379 rare diseases in 2019 was nearly $1 trillion, with 60% of those costs being shouldered directly by families and society.
  • “Medical costs for rare diseases are inevitable, but avoidable costs from delayed diagnosis not only place financial strain on individuals and families but also divert crucial healthcare funds.
  • For individuals with late onset Pompe disease, delayed diagnosis increased mean annual direct medical costs in the year of diagnosis by approximately $50,000 per patient compared with timely diagnosis.
  • For more information about “Cost Benefits of Early Diagnosis and Screening in Rare Disease” study, visit the study website at everylifefoundation.org/delayed-diagnosis-study .

OneOncology and Its Practice Partners Celebrate Five Years of Cancer Care Excellence

Retrieved on: 
Wednesday, September 13, 2023
Partnership, Radiation, Pharmacy, Workflow, Disease, Cancer, Nuclear medicine, Genetic counseling, MD, Patient, Physician, Medicine, Palliative care, Chief medical informatics officer, Neoplasm, FDA, Safety, Nursing, Pharmaceutical industry

60 to 320 cancer care sites across all practice partners.

Key Points: 
  • 60 to 320 cancer care sites across all practice partners.
  • "As we've grown and enhanced world-class cancer care in communities across the country, strengthening practice independence and empowering their decision-making has always been our north star.
  • Since OneOncology was founded, OneOncology has:
    Enabled its practice partners to enroll more than 800 patients in interventional and observational clinical trials.
  • "OneOncology has accomplished a lot for its practice partners in five years," Dr. Patton said.

Synapticure Welcomes Joe Leinbach as Chief Operating Officer and Expands Coverage to Additional Neurological Conditions

Retrieved on: 
Wednesday, September 6, 2023
Net, Insurance, ER, Huntington's disease, Patient, Neurodegenerative disease, St. Louis Fed Financial Stress Index, Health, DC, Quality of life, Lou Gehrig, Neurology, Michael D. Leinbach, Lewy body dementias, Medicare, NPS, Genetic counseling, Alzheimer's disease, Parkinson's disease, Retirement Insurance Benefits, Physician, Growth, Entrepreneurship, Diagnosis, ALS, Mental health, FTD, Family, Psychiatry, Caregiver, Health care, Nursing, Pharmaceutical industry

CHICAGO, Sept. 6, 2023 /PRNewswire/ --  Synapticure, a virtual clinic transforming treatment and outcomes for individuals and their caregivers living with neurodegenerative diseases, announced Joe Leinbach has joined as the company's first Chief Operating Officer. Leinbach joins at a critical time for the company's expansion into additional neurodegenerative conditions including Alzheimer's and related Dementias, while creating new ways to expand patient access through innovative partnerships with health systems and health plans.

Key Points: 
  • A veteran of early stage value-based care innovators, Leinbach has driven growth and operational success in leadership roles at Cityblock Health and Evolent Health.
  • Joe will lead the company's next phase of growth and efforts to implement innovative models that directly benefit patients and partners.
  • Synapticure's services also include behavioral health (psychiatry and therapy), genetic counseling, in-home physical therapy/occupational therapy, and speech language therapy.
  • Patients and providers can sign up or refer patients to Synapticure for a free consultation at www.synapticure.com or call us at (855) 255-5917.

ProPhase Labs Announces Financial Results for the Three Months Ended June 30, 2023

Retrieved on: 
Thursday, August 10, 2023
Nebula, Mayo Clinic, CPT, Marketing, Internet, George Church, Science, Stella, Nebula Genomics, Patient, Whole genome sequencing, Hospital Insurance and Diagnostic Services Act, Three Months, Automation, HRSA, Heart, Therapy, Diagnosis, Hope, Research, Endoscopy, COVID-19 testing, CLIA, Corporation, Medicine, Genetic, Growth, Prophase, System, CDX, IND, Exercise, DNA, Operation Linebacker, Absorption, History, Genetics, Algorithm, FDM, Omicron, Negotiation, Genomics, Cold, Sale, Public expenditure, Genetic counseling, EBITDA, Food, Renewable energy, Pharmaceutical industry, Retail, Cryptocurrency, Tourism, Fine chemical, Vaccine, Microscope, Q2, COVID-19, Bosc

Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023. The Company announced that despite the slowdown in the Covid-19 testing business, and the significant ramp-up of its multiple growth-oriented subsidiaries, adjusted EBITDA loss for the quarter ended June 30,2023 was $2.2 million in Q2 and that the Company enjoys robust net working capital of $40.2 million as of June 30, 2023.

Key Points: 
  • Company to hold a conference call Thursday, August 10, 2023, at 11:00 AM ET
    Garden City, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today reported its financial and operational results for the three months ended June 30, 2023.
  • Revenues grew greater than 100% year-over-year for the six months ended June 30, 2023 as compared to the six months ended June 30, 2022.
  • Three Months Ended June 30, 2023 as compared to the Three Months Ended June 30, 2022.
  • Diagnostic services costs for the three months ended June 30, 2023 were $0.6 million compared to $1.8 million for the three months ended June 30, 2022.

Tampa General Hospital Named to Becker's Hospital Review's 2023 List of 'Hospitals and Health Systems with Great Heart Programs'

Retrieved on: 
Monday, July 17, 2023
Becker's, Arrhythmia, Mitral valve repair, Postperfusion syndrome, Hospital, X-ray, Division, Patient, Electrophysiology, Health, News, Heart, Rib, CT, Business development, Heart failure, Leg, Artery, U.S. News & World Report, Tampa General Hospital, Diagnosis, Becker's Hospital Review, Coronary artery disease, Transesophageal echocardiogram, Vascular surgery, Becker, Partnership, Surgeon, Enhanced Primary Care Case Management Program, Sri Jayadeva Institute of Cardiovascular Sciences and Research, Genetic counseling, MRI, TGH, Airline, Pharmaceutical industry, Dentistry, Medical imaging, Medical device, Quality, Tampa Bay, Cardiology

TAMPA, Fla., July 17, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the top hospitals and health systems in the U.S. delivering exemplary heart and vascular care, according to the 2023 Becker's Hospital Review's "100 Hospitals and Health Systems with Great Heart Programs" list.

Key Points: 
  • TAMPA, Fla., July 17, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the top hospitals and health systems in the U.S. delivering exemplary heart and vascular care, according to the 2023 Becker's Hospital Review's "100 Hospitals and Health Systems with Great Heart Programs" list.
  • Tampa General's inclusion on the list reflects the academic health system's commitment to providing comprehensive, individualized care for patients with a variety of heart and vascular conditions.
  • U.S. News & World Report also ranked Tampa General as "high performing" in Heart Attack and Heart Failure care for 2022-23.
  • Inclusion on the Becker's "100 Hospitals and Health Systems with Great Heart Programs" list is the latest among several high-profile recognitions for Tampa General Hospital, including:

Quest Launches Consumer-Initiated Genetic Test on questhealth.com to Deliver Personalized, Actionable Health Risk Insights

Retrieved on: 
Tuesday, July 11, 2023
Heart, DNA, NGS, Health status of Asian Americans, Chart, Breast, Genetic counseling, Genetics, Tay–Sachs disease, Collection, Anti-transglutaminase antibodies, FACMG, Risk, Patient, Physician, Cystic fibrosis, Genetic testing, Gene, NYSE, DGX, Genome, Breast cancer, Disease, Vaccine, Pharmaceutical industry, Nursing, Quest Diagnostics, Quest, Doctor of Philosophy

SECAUCUS, N.J., July 11, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the leader in diagnostic information services, today announced the launch of its first consumer-initiated genetic test, now exclusively available through the company's consumer health business at questhealth.com. Called Genetic Insights, the new offering helps people understand their potential risk of developing certain inheritable health conditions, with advanced technology and end-to-end support that includes personalized health reports and access to genetic counseling.

Key Points: 
  • Called Genetic Insights , the new offering helps people understand their potential risk of developing certain inheritable health conditions, with advanced technology and end-to-end support that includes personalized health reports and access to genetic counseling.
  • "Genetic Insights goes beyond the typical consumer genetic test.
  • Based on the results of this test and personal or family health history, an individual's physician may suggest additional genetic testing.
  • The Genetics Insights test does not identify genetic risk markers of all known inheritable diseases.

Parent Project Muscular Dystrophy Hosts 29th Annual Conference in Dallas, Texas

Retrieved on: 
Wednesday, June 28, 2023
Learning, Therapy, PTC Therapeutics, Duchenne muscular dystrophy, Gene, Furlong, Pfizer, Life, Face, Breakout box, Parent, Workplace, Becker muscular dystrophy, Research, Grandparent, Brain, Respiratory therapist, Behavior, Senior counsel, Genetic counseling, Sarepta Therapeutics, App, Sibling, Physician, PPMD, Motivation, Cardiology, Caregiver, Conference, News, Platinum, Nursing, Pharmaceutical industry, Birth control, Residential care, Music, Video game, Becker, Duchenne

WASHINGTON, June 28, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), will host their 2023 Annual Conference in Dallas, Texas, June 29 - July 1. Each year, the Duchenne community gathers to learn about the latest progress in the fight to end Duchenne and connect with leading experts. Now in its 29th year, after introducing a hybrid format featuring both in-person and virtual participation options in 2022, PPMD's Annual Conference engages more of the Duchenne community than ever before.  

Key Points: 
  • WASHINGTON, June 28, 2023 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , will host their 2023 Annual Conference in Dallas, Texas, June 29 - July 1.
  • Now in its 29th year, after introducing a hybrid format featuring both in-person and virtual participation options in 2022, PPMD's Annual Conference engages more of the Duchenne community than ever before.
  • PPMD's 2023 Annual Conference agenda will feature stories from multiple keynote speakers, and interactive discussion panels addressing comprehensive, multi-dimensional approaches to care for Duchenne.
  • Becker-specific breakout sessions, including discussions on neuromuscular care, cardiology, genetic counseling, and physical therapy, as well as updates about emerging therapies for Becker muscular dystrophy.